In particular, lung adenocarcinomas with mutations in the gene encoding the epidermal growth factor receptor (EGFR) are uniquely sensitive to EGFR blockade with specific tyrosine kinase inhibitors (TKIs) (7, 8). The gene discussed is EGFR; the disease is lung adenocarcinoma.